Navigation Links
Vaccine Against the Chikungunya Virus in Development by a Public-Private Partnership
Date:2/4/2009

LEIDEN, The Netherlands, February 4 /PRNewswire/ -- Top Institute Pharma (TI Pharma) has formed a consortium with Wageningen University, Erasmus University Medical Centre and Nobilon, a subsidiary of Schering-Plough, to develop a 'proof of concept' vaccine against the Chikungunya virus. This vaccine aims to reduce the rate of Chikungunya infections.

Viral disease epidemics have increased in incidence around the world in recent decades. One of these diseases is caused by the Chikungunya virus, which is transmitted by mosquitoes. Originally, the disease was confined to Africa, but later spread to countries in Asia. Several cases of this disease have now been confirmed in various European countries. It appears to be spread by travelers returning from affected countries. In France, there have been more than one hundred cases and in Italy a few hundred. It seems evident that the mosquitoes able of transmitting this disease are also present in Europe. Whether or not the virus will spread further throughout Europe remains to be seen.

Virologist Ab Osterhaus, one of the research supervisors, says: "Considering the increasing spread of the Chikungunya virus in Asia, and probably also in Europe in the future, it is important to develop a vaccine against this virus that can be used not only to protect people living in the endemic area, but also travelers traveling to those areas.

The groups that are going to work together in this project have extensive expertise in the field of exotic viral infectious diseases as well as significant experience with the newest technologies in the field of vaccine development."

This TI Pharma project has a budget of EUR 2.3 million and aims to achieve a 'proof of concept' vaccine by the year 2012.

Chikungunya is a serious viral illness, which is transmitted by the Asian tiger mosquito. The disease causes a sudden high fever, a rash and intense joint pain, which can result in disability, which can last several months. There is currently no vaccine or treatment available to combat this disease.


'/>"/>
SOURCE TI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
6. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. New nanoparticle vaccine is more effective but less expensive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016  Bioethics International, ... how medicines are researched, developed, marketed and made accessible to ... BMJ Open had named the publication of the ... for 2015. The publication is also featured as one of ... published in the last year that are most frequently read. ...
(Date:2/11/2016)... 2016  Dovetail Genomics™ LLC today announced that it ... a planned metagenomic genome assembly service. Richard Green ... assembly method in a talk on Friday, February 12 ... conference in Orlando, Fla. ... is difficult. Using its proprietary Chicago ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... regenerative medicine, has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network ... and phsyicians in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, ...
(Date:2/10/2016)... -- The Maryland House of Delegates and House Speaker ... Maryland School of Medicine Dean E. Albert Reece ... System President and CEO Robert Chrencik , MBA, ... given to the public by the leader of the ... and Mr. Chrencik for their contributions to our statewide ...
Breaking Biology Technology:
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. ... in West Chester, Ohio announced ... winning service staff, based in Austin, Texas ... and ability to provide modifications, installations and technical support ... , CEO of PLUS, commented, "PLUS has provided world ...
Breaking Biology News(10 mins):